Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:ACLX NASDAQ:DYN NASDAQ:MRUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$41.31-1.2%$41.11$16.50▼$48.45$3.95BN/A9,381 shs1,859 shsACLXArcellx$71.22+2.1%$69.67$47.86▼$107.37$3.85B0.28601,538 shs329,486 shsDYNDyne Therapeutics$13.48-0.1%$10.63$6.36▼$37.08$1.92B1.13.00 million shs2.26 million shsMRUSMerus$66.62+0.5%$62.02$33.19▼$69.20$4.98B1.19575,232 shs589,537 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.22%-0.22%+9.87%+47.69%+4,130,999,900.00%ACLXArcellx+2.11%+1.89%-1.19%+7.50%+7.71%DYNDyne Therapeutics-0.15%-1.17%+31.51%-3.65%-57.80%MRUSMerus+0.48%-0.98%-0.46%+18.94%+32.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AACLXArcellx2.1804 of 5 stars3.60.00.00.03.62.50.0DYNDyne Therapeutics3.7931 of 5 stars4.51.00.00.03.65.00.0MRUSMerus3.003 of 5 stars3.53.00.00.03.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AACLXArcellx 3.13Buy$114.3160.50% UpsideDYNDyne Therapeutics 3.06Buy$34.07152.72% UpsideMRUSMerus 3.08Buy$88.7533.22% UpsideCurrent Analyst Ratings BreakdownLatest DYN, AAPG, MRUS, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$90.008/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$90.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $13.008/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$97.00 ➝ $96.008/4/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/31/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$93.00 ➝ $133.007/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $23.007/29/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$37.00 ➝ $31.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M28.58N/AN/A$1.01 per share40.90ACLXArcellx$107.94M36.59N/AN/A$7.07 per share10.07DYNDyne TherapeuticsN/AN/AN/AN/A$4.02 per shareN/AMRUSMerus$36.13M139.45N/AN/A$11.13 per share5.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)Latest DYN, AAPG, MRUS, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AACLXArcellxN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53ACLXArcellxN/A3.813.81DYNDyne Therapeutics0.1716.8316.83MRUSMerusN/A8.398.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AACLXArcellx96.03%DYNDyne Therapeutics96.68%MRUSMerus96.14%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AACLXArcellx8.35%DYNDyne Therapeutics20.77%MRUSMerus3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60092.96 millionN/AN/AACLXArcellx8055.46 million50.83 millionOptionableDYNDyne Therapeutics100142.26 million112.72 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableDYN, AAPG, MRUS, and ACLX HeadlinesRecent News About These Companies14,704 Shares in Merus N.V. $MRUS Acquired by Walleye Capital LLCSeptember 3 at 4:19 AM | marketbeat.comMerus N.V. $MRUS is Paradigm Biocapital Advisors LP's 4th Largest PositionSeptember 2 at 7:09 AM | marketbeat.comDAFNA Capital Management LLC Boosts Stake in Merus N.V. $MRUSSeptember 1 at 7:14 AM | marketbeat.comDriehaus Capital Management LLC Has $52.79 Million Holdings in Merus N.V. $MRUSAugust 31, 2025 | marketbeat.comMerus N.V. $MRUS is Siren L.L.C.'s 10th Largest PositionAugust 31, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Hits New 12-Month High - Should You Buy?August 30, 2025 | marketbeat.comMerus N.V. $MRUS Shares Sold by Tri Locum Partners LPAugust 30, 2025 | marketbeat.comMerus N.V. $MRUS Shares Sold by Price T Rowe Associates Inc. MDAugust 30, 2025 | marketbeat.comAffinity Asset Advisors LLC Sells 67,279 Shares of Merus N.V. $MRUSAugust 28, 2025 | marketbeat.comMerus to Present at the 2025 Wells Fargo Healthcare ConferenceAugust 28, 2025 | globenewswire.comMerus (NASDAQ:MRUS) Now Covered by Analysts at Alliance Global PartnersAugust 27, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Coverage Initiated at Alliance Global PartnersAugust 27, 2025 | americanbankingnews.comT. Rowe Price Investment Management Inc. Cuts Position in Merus N.V. $MRUSAugust 26, 2025 | marketbeat.comAlliance Global Partners Initiates Coverage of Merus N.V. (MRUS) with Buy RecommendationAugust 25, 2025 | msn.comMerus initiated with a Buy at Alliance Global PartnersAugust 25, 2025 | msn.comWellington Management Group LLP Purchases 1,220,519 Shares of Merus N.V. $MRUSAugust 23, 2025 | marketbeat.comAberdeen Group plc Has $7.24 Million Stock Position in Merus N.V. $MRUSAugust 23, 2025 | marketbeat.comCarmignac Gestion Invests $5.13 Million in Merus N.V. $MRUSAugust 21, 2025 | marketbeat.comMerus N.V. $MRUS Shares Sold by Algert Global LLCAugust 21, 2025 | marketbeat.comMerus N.V. $MRUS Shares Bought by Invesco Ltd.August 20, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Sets New 1-Year High - What's Next?August 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Buy the Dip? These Earnings Misses Offer Long-Term UpsideBy Nathan Reiff | August 7, 2025DYN, AAPG, MRUS, and ACLX Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$41.31 -0.51 (-1.22%) As of 09/3/2025 03:50 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Arcellx NASDAQ:ACLX$71.22 +1.47 (+2.11%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$71.22 0.00 (0.00%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Dyne Therapeutics NASDAQ:DYN$13.48 -0.02 (-0.15%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$13.86 +0.38 (+2.78%) As of 09/3/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Merus NASDAQ:MRUS$66.62 +0.32 (+0.48%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$65.25 -1.37 (-2.06%) As of 09/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
